GDPA;

• 1:广东省药学会

摘要(Abstract)：

<正>(2021年8月11日发布，在线出版日期：2021-09-02)特应性皮炎（atopic dermatitis,AD）是一种慢性、复发性、炎症性皮肤疾病，通常伴有剧烈瘙痒，且合并过敏性鼻炎、哮喘等特应性疾病，故通常被认为是一种系统性疾病。近年来AD患病率逐渐增加，且其中重度患者比例高、儿童患病持续时间长，给患者的工作、学习、生活带来了极大的不便和影响。为规范和指导AD的诊断和治疗，中华医学会皮肤性病学分会免疫学组制定了《中国特应性皮炎诊疗指南（2020版）》，给AD的诊疗提供了科学和权威的参考依据。该指南主要从临床治疗角度进行了阐述，涵盖了AD的定义、患病率、发病机制、分类、诊断、预防和治疗方案，但由于篇幅所限，在药物治疗方面的信息只做了概括性介绍。一方面，AD的治疗药物较多，传统的主要包括外用药物（外用糖皮质激素、外用钙调神经磷酸酶抑制剂）和系统用药（抗组胺药、免疫抑制剂、糖皮质激素）。

关键词(KeyWords)： 特应性皮炎;合理用药
atopic dermatitia(AD);rational use of drugs

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors):
GDPA;

参考文献(References)：

• [1] Brown S,Reynolds N J.Atopic and non-atopic eczema[J].BMJ,2006,332(7541):584-588.
• [2] Guo Y,Li P,Tang J,et al.Prevalence of atopic dermatitis in Chinese children aged 1-7ys[J].Sci Rep,2016,6:29751.
• [3] Akdis C A,Akdis M,Bieber T,et al.Diagnosis and treatment of atopic dermatitis in children and adults:European academy of allergology and clinical immunology/American academy of allergy,asthma and immunology/PRACTALL consensus report[J].Allergy,2006,61(8):969-987.
• [4] Suárez-Fari as M,Dhingra N,Gittler J,et al.Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis[J].J Allergy Clin Immunol,2013,132(2):361-370.
• [5] Chan T C,Sanyal R D,Pavel A B,et al.Atopic dermatitis in Chinese patients shows TH2/TH17 skewing with psoriasiform features[J].J Allergy Clin Immunol,2018,142(3):1013-1017.
• [6] Liu P,Zhao Y,Mu Z L,et al.Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis[J].Chin Med J (Engl),2016,129(7):757-762.
• [7] Liu P,Zhao Y,Mu Z L,et al.Clinical features of adult/adolescent atopic dermatitis and Chinese criteria for atopic dermatitis[J].Chin Med J (Engl),2016,129(7):757-762.
• [8] 中华医学会皮肤性病学分会免疫学组，特应性皮炎协作研究中心.中国特应性皮炎诊疗指南(2020版)[J].中华皮肤科杂志，2020,53(2):81-88.
• [9] 中国医师协会皮肤科医师分会过敏性疾病专业委员会.特应性皮炎瘙痒管理专家共识[J].中华皮肤科杂志，2021,54(5):391-393.
• [10] Smith S,Baker C,Gebauer K,et al.Atopic dermatitis in adults:An Australian management consensus[J].Australas J Dermatol,2020,61(1):23-32.
• [11] Wollenberg A,Szepietowski J,Taieb A,et al.Corrigendum:Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children:Part I[J].J Eur Acad Dermatol Venereol,2019,33(7):1436.
• [12] 中国中西医结合学会皮肤性病专业委员会环境与职业性皮肤病学组.规范外用糖皮质激素类药物专家共识[J].中华皮肤科杂志，2015,48(2):73-75.
• [13] 中华医学会皮肤性病学分会儿童皮肤病学组.中国儿童特应性皮炎诊疗共识(2017版)[J].中华皮肤科杂志，2017,50(11):784-789.
• [14] Vestergaard C,Wollenberg A,Barbarot S,et al.European task force on atopic dermatitis position paper:Treatment of parental atopic dermatitis during preconception,pregnancy and lactation period[J].J Eur Acad Dermatol Venereol,2019,33(9):1644-1659.
• [15] Cury Martins J,Martins C,Aoki V,et al.Topical tacrolimus for atopic dermatitis[J].Cochrane Database Syst Rev,2015.Doi:10.1002/14651858.cd009864.
• [16] Paller A S,Lebwohl M,Fleischer A B,et al.Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis:Results from 3 randomized,comparative studies[J].J Am Acad Dermatol,2005,52(5):810-822.
• [17] Paller A S,Lebwohl M,Fleischer A B,et al.Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis:Results from 3 randomized,comparative studies[J].J Am Acad Dermatol,2005,52(5):810-822.
• [18] Sigurgeirsson B,Boznanski A,Todd G,et al.Safety and efficacy of pimecrolimus in atopic dermatitis:A 5-year randomized trial[J].Pediatrics,2015,135(4):597-606.
• [19] Wollenberg A,Barbarot S,Bieber T,et al.Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children:Part II[J].J Eur Acad Dermatol Venereol,2018,32(6):850-878.
• [20] Schlessinger J,Shepard J S,Gower R,et al.Safety,effectiveness,and pharmacokinetics of crisaborole in infants aged 3 to 24 months with mild-to-moderate atopic dermatitis:A phase IV open-label study (CrisADe CARE 1)[J].Am J Clin Dermatol,2020,21(2):275-284.
• [21] Kim B S,Howell M D,Sun K,et al.Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream[J].J Allergy Clin Immunol,2020,145(2):572-582.
• [22] Paller A S,Stein Gold L,Soung J,et al.Efficacy and patient-reported outcomes from a phase 2b,randomized clinical trial of tapinarof cream for the treatment of adolescents and adults with atopic dermatitis[J].J Am Acad Dermatol,2021,84(3):632-638.
• [23] Matterne U,B hmer M M,Weisshaar E,et al.Oral H1 antihistamines as ‘add-on’ therapy to topical treatment for eczema[J].Cochrane Database Syst Rev,2019,1:CD012167.
• [24] Katoh N,Ohya Y,Ikeda M,et al.Japanese guidelines for atopic dermatitis 2020[J].Allergol Int,2020,69(3):356-369.
• [25] 中华医学会变态反应学分会，儿童过敏和哮喘学组，中华医学会儿科学分会呼吸学组，等.抗组胺H1受体药在儿童常见过敏性疾病中应用的专家共识[J].中国实用儿科杂志，2018,33(3):161-170.
• [26] 中国中西医结合学会皮肤性专业委员会环境与职业性皮肤病学组.抗组胺药在皮肤科应用专家共识[J].中国皮肤科杂志，2017,50(6):393-396.
• [27] He A,Feldman S R,Fleischer A B.An assessment of the use of antihistamines in the management of atopic dermatitis[J].J Am Acad Dermatol,2018,79(1):92-96.
• [28] FDA.Benadryl (diphenhydramine):Drug Safety Communication-Serious ProblemswithHighDosesoftheAllergyMedicine[EB/OL].(2020-09-24)[2021-07-16].https://www.fda.gov/safety/medical-product-safety-information/benadryl-diphenhydramine-drug-safety-communication-serious-problems-high-doses-allergy-medicine.
• [29] Garrido C C,Blasco M G,Tercedor S J.Oral cyclosporine weekend therapy:A new maintenance therapeutic option in patients with severe atopic dermatitis[J].Pediatr Dermatol,2015,32(4):551-552.
• [30] Sidbury R,Davis D M,Cohen D E,et al.Guidelines of care for the management of atopic dermatitis:Section 3.Management and treatment with phototherapy and systemic agents[J].J Am Acad Dermatol,2014,71(2):327-349.
• [31] Garcia-Ortiz R E,Rodriguez M D A.Pancytopenia associated with the interaction of allopurinol and azathioprine[J].J Pharm Technol,1991,7(6):224-226.
• [32] 国家卫生健康委员会.卫生部办公厅关于印发《糖皮质激素类药物临床应用指导原则》的通知[Z].卫办医政发[2011]23号，2011-02-16.
• [33] Sanofi Winthrop Industrie.度普利尤单抗注射液说明书[Z].2020-06.
• [34] DUPIXENT (dupilumab) injection prescribing information[Z].Approved by FDA,2020-05.
• [35] Dupixent :EPAR- Product Information[Z].Approved by EMA,2021-01-22.
• [36] Helen H,Emma G Y.JAK Inhibitors for Atopic Dermatitis:An Update[J].American Journal of Clinical Dermatology,2019,20(2):181-192.
• [37] Maria A R,Tiago T.JAK/STAT inhibitors for the treatment of atopic dermatitis [J].J Dermatolog Treat,2020,31(1):33-40.
• [38] Yael R Y,Emma G Y.New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines [J].Ann Allergy Asthma Immunol,2020,124(1):28-35.
• [39] Ana B P,Teresa S,Hyun J K,et al.Oral Janus kinase/SYK inhibition (ASN002) suppresses inflammation and improves epidermal barrier markers in patients with atopic dermatitis[J].J Allergy Clin Immunol,2019,144(4):1011-1024.
• [40] 唐晓楠，张海婧，王文杰，等.靶向 JAK 治疗自身免疫病的小分子药物研究进展[J].药学学报，2018,53 (10):1591-1597.
• [41] OLUMIANT (baricitinib) FDA说明书[Z].2020-07.
• [42] XELJANZ (tofacitinib) FDA说明书[Z].2020-09.
• [43] RINVOQ (upadacitinib) FDA说明书[Z].2020-07.
• [44] JAKAFI (ruxolitinib) FDA说明书[Z].2020-01.
• [45] Stephen C P,Ana B P,Kimberly M,et al.A Phase 1b,Randomized,Single-Center Trial of Topical Cerdulatinib (DMVT-502) in Patients with Mild-to-Moderate Atopic Dermatitis[J].J Invest Dermatol,2021,141(7):1847-1851.